肝窦阻塞综合征的研究进展

张明

doi:10.12449/JCH240104

肝窦阻塞综合征的研究进展

DOI: 10.12449/JCH240104

张明^, ,

南京大学医学院附属鼓楼医院消化内科，南京 210008

利益冲突声明：本文不存在任何利益冲突。

详细信息

通信作者:
张明， mg0923@163.com （ORCID： 0009-0009-7742-3128）

计量
- 文章访问数: 685
- HTML全文浏览量: 123
- PDF下载量: 182
- 被引次数: 0
出版历程
- 收稿日期: 2023-12-11
- 录用日期: 2023-12-20
- 出版日期: 2024-01-23

Research advances in hepatic sinusoidal obstruction syndrome

Ming ZHANG^{,
,}

Department of Gastroenterology，Affiliated Drum Tower Hospital of Nanjing University Medical School，Nanjing 210008，China

More Information

Corresponding author: ZHANG Ming， mg0923@163.com （ORCID： 0009-0009-7742-3128）

摘要

摘要: 肝窦阻塞综合征（HSOS）也被称为肝小静脉闭塞病，是一类由各种原因导致的肝血窦阻塞和肝小静脉闭塞纤维化的肝脏血管性疾病。本文系统阐述了HSOS的认识过程和命名演变、病因和发病机制、临床表现、诊断与鉴别诊断、预防和治疗等方面的研究进展。HSOS可发生于接受骨髓造血干细胞移植清髓处理、放射/化学治疗和摄入含吡咯生物碱药物的人群，常见临床表现为腹胀、肝区胀痛、腹水、黄疸、肝大等。针对不同病因，HSOS的诊断标准也不相同，需要与其他药物性肝病、肝静脉流出道梗阻等疾病相鉴别。去纤苷和低分子肝素分别对造血干细胞和吡咯生物碱相关的HSOS具有治疗作用，奥沙利铂化疗导致的HSOS目前尚无有效治疗药物。
- 肝窦阻塞综合征 /
- 造血干细胞移植 /
- 奥沙利铂
Abstract: Hepatic sinusoidal obstruction syndrome （HSOS）， also known as hepatic veno-occlusive disease， is hepatic vascular disease of hepatic sinusoidal obstruction and hepatic venular occlusion and fibrosis due to various causes. This article systematically elaborates on the research advances in HSOS from the aspects of understanding and naming， etiology and pathogenesis， clinical manifestation， diagnosis and differential diagnosis， prevention， and treatment. HSOS can occur in patients receiving bone marrow hematopoietic stem cell transplantation， radiotherapy/chemotherapy， and medication containing pyrrolidine alkaloids， and the common clinical manifestations of HSOS include abdominal distension， distending pain in the liver area， ascites， jaundice， and hepatomegaly. The diagnostic criteria for HSOS vary with etiology， and it needs to be differentiated from other diseases such as drug-induced liver diseases and hepatic venous outflow tract obstruction. Defibrotide and low-molecular-weight heparin have a therapeutic effect on HSOS associated with hematopoietic stem cells and pyrrolidine alkaloids， respectively， and there are currently no effective drugs for HSOS caused by oxaliplatin chemotherapy.
- Hepatic Sinus Obstruction Syndrome /
- Hematopoietic Stem Cell Transplantation /
- Oxaliplatin

HTML全文

参考文献(28)

[1]	VALLA DC, CAZALS-HATEM D. Sinusoidal obstruction syndrome[J]. Clin Res Hepatol Gastroenterol, 2016, 40( 4): 378- 385. DOI: 10.1016/j.clinre.2016.01.006.
[2]	FAN CQ, CRAWFORD JM. Sinusoidal obstruction syndrome(hepatic veno-occlusive disease)[J]. J Clin Exp Hepatol, 2014, 4( 4): 332- 346. DOI: 10.1016/j.jceh.2014.10.002.
[3]	Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome(2017, Nanjing)[J]. J Clin Hepatol, 2017, 33( 9): 1627- 1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003. 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年, 南京)[J]. 临床肝胆病杂志, 2017, 33( 9): 1627- 1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.
[4]	ZHUGE YZ, LIU YL, XIE WF, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol, 2019, 34( 4): 634- 642. DOI: 10.1111/jgh.14612.
[5]	BRAS G, JELLIFFE DB, STUART KL. Veno-occlusive disease of liver with nonportal type of cirrhosis, occurring in Jamaica[J]. AMA Arch Pathol, 1954, 57( 4): 285- 300.
[6]	RUBBIA-BRANDT L, AUDARD V, SARTORETTI P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer[J]. Ann Oncol, 2004, 15( 3): 460- 466. DOI: 10.1093/annonc/mdh095.
[7]	ZHU C, REN XH, LIU D, et al. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome[J]. Toxicology, 2021, 460: 152882. DOI: 10.1016/j.tox.2021.152882.
[8]	CORBACIOGLU S, GRUPP SA, RICHARDSON PG, et al. Prevention of veno-occlusive disease/sinusoidal obstruction syndrome: A never-ending story and no easy answer[J]. Bone Marrow Transplant, 2023, 58( 8): 839- 841. DOI: 10.1038/s41409-023-02007-2.
[9]	de LÉDINGHEN V, VILLATE A, ROBIN M, et al. Sinusoidal obstruction syndrome[J]. Clin Res Hepatol Gastroenterol, 2020, 44( 4): 480- 485. DOI: 10.1016/j.clinre.2020.03.019.
[10]	MA YX, FENG YL, WU YY, et al. Toxic pyrrolizidine alkaloids in Chinese herbal medicine: Control status and advances in analytical method[J]. Chin Tradit Herb Drugs, 2021, 52( 24): 7645- 7657. DOI: 10.7501/j.issn.0253-2670.2021.24.028. 马跃新, 冯有龙, 吴嫣艳, 等. 中草药中毒性吡咯里西啶类生物碱分析方法研究进展及控制现状[J]. 中草药, 2021, 52( 24): 7645- 7657. DOI: 10.7501/j.issn.0253-2670.2021.24.028.
[11]	ÖZKAN HA, ÖZKAN SG. Hepatic veno-occlusive disease(sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation in adult patients: Diagnosis, incidence, prophylaxis, and treatment[J]. Transfus Apher Sci, 2022, 61( 1): 103372. DOI: 10.1016/j.transci.2022.103372.
[12]	MOHTY M, MALARD F, ABECASSIS M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: A new classification from the European Society for Blood and Marrow Transplantation[J]. Bone Marrow Transplant, 2016, 51( 7): 906- 912. DOI: 10.1038/bmt.2016.130.
[13]	WAESPE N, STREBEL S, JURKOVIC MLAKAR S, et al. Genetic predictors for sinusoidal obstruction syndrome-a systematic review[J]. J Pers Med, 2021, 11( 5): 347. DOI: 10.3390/jpm11050347.
[14]	KUMAR A, PALEK R, LISKA V. A critical analysis of experimental animal models of sinusoidal obstruction syndrome[J]. J Clin Exp Hepatol, 2019, 9( 3): 345- 353. DOI: 10.1016/j.jceh.2018.07.002.
[15]	TODA R, SEO S, UEMOTO Y, et al. Clinically relevant model of oxaliplatin-induced sinusoidal obstruction syndrome[J]. Hepatol Res, 2023, 53( 2): 145- 159. DOI: 10.1111/hepr.13842.
[16]	CALISTRI L, RASTRELLI V, NARDI C, et al. Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis[J]. World J Gastroenterol, 2021, 27( 46): 7866- 7893. DOI: 10.3748/wjg.v27.i46.7866.
[17]	LIU L, ZHANG W, ZHUGE YZ. Review on diagnostic criteria of hepatic sinusoidal obstruction syndrome[J]. Chin J Hepatol, 2020, 28( 12): 1064- 1068. DOI: 10.3760/cma.j.cn501113-20190415-00124. 刘璐, 张玮, 诸葛宇征. 肝窦阻塞综合征诊断标准综述[J]. 中华肝脏病杂志, 2020, 28( 12): 1064- 1068. DOI: 10.3760/cma.j.cn501113-20190415-00124.
[18]	CHAO N. How I treat sinusoidal obstruction syndrome[J]. Blood, 2014, 123( 26): 4023- 4026. DOI: 10.1182/blood-2014-03-551630.
[19]	CORBACIOGLU S. Sinusoidal obstruction syndrome(SOS) and defibrotide: We are not there yet[J]. Transplant Cell Ther, 2023, 29( 5): 287- 288. DOI: 10.1016/j.jtct.2023.03.032.
[20]	COLECCHIA A, RAVAIOLI F, SESSA M, et al. Liver stiffness measurement allows early diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome in adult patients who undergo hematopoietic stem cell transplantation: Results from a monocentric prospective study[J]. Biol Blood Marrow Transplant, 2019, 25( 5): 995- 1003. DOI: 10.1016/j.bbmt.2019.01.019.
[21]	ZHANG W, LIU L, ZHANG M, et al. Validation of the Nanjing criteria for diagnosing pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome[J]. J Clin Transl Hepatol, 2021, 9( 3): 345- 352. DOI: 10.14218/JCTH.2020.00124.
[22]	CUTLER C, KIM HT, AYANIAN S, et al. Prediction of veno-occlusive disease using biomarkers of endothelial injury[J]. Biol Blood Marrow Transplant, 2010, 16( 8): 1180- 1185. DOI: 10.1016/j.bbmt.2010.02.016.
[23]	TONG YR, ZHANG M, QI ZX, et al. Hepatic venous occlusion type of budd-chiari syndrome versus pyrrolizidine alkaloid-induced hepatic sinusoidal obstructive syndrome: A multi-center retrospective study[J]. J Pers Med, 2023, 13( 4): 603. DOI: 10.3390/jpm13040603.
[24]	PENG C, ZHANG X, ZHANG F, et al. Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective multicenter cohort study[J]. Eur J Gastroenterol Hepatol, 2020, 32( 9): 1168- 1178. DOI: 10.1097/MEG.0000000000001630.
[25]	WU F, YU JA, GAN HY, et al. Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. Sci Rep, 2021, 11: 21743. DOI: 10.1038/s41598-021-01201-w.
[26]	WANG X, ZHANG W, ZHANG M, et al. Development of a Drum Tower Severity Scoring(DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. Hepatol Int, 2022, 16( 3): 669- 679. DOI: 10.1007/s12072-021-10293-5.
[27]	XIAO J, TU J, ZHANG H, et al. Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt[J]. Hepatol Int, 2021, 15( 3): 720- 729. DOI: 10.1007/s12072-020-10126-x.
[28]	RUUTU T, JUVONEN E, REMBERGER M, et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: Long-term follow-up of a randomized study[J]. Biol Blood Marrow Transplant, 2014, 20( 1): 135- 138. DOI: 10.1016/j.bbmt.2013.10.014.